Status:
COMPLETED
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
Lead Sponsor:
Northwestern University
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.
Eligibility Criteria
Inclusion
- Patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder.
Exclusion
- Patients with DSM-IV diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.
Key Trial Info
Start Date :
November 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 16 2024
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT00178932
Start Date
November 1 1998
End Date
May 16 2024
Last Update
March 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Psychiatric Hospital at Vanderbilt
Nashville, Tennessee, United States, 37212